328 related articles for article (PubMed ID: 29208014)
1. Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus.
Martin M; Smoląg KI; Björk A; Gullstrand B; Okrój M; Leffler J; Jönsen A; Bengtsson AA; Blom AM
Arthritis Res Ther; 2017 Dec; 19(1):266. PubMed ID: 29208014
[TBL] [Abstract][Full Text] [Related]
2. Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis.
Qin S; Wang X; Wang J; Wu H
Lupus; 2024 Feb; 33(2):111-120. PubMed ID: 38227433
[No Abstract] [Full Text] [Related]
3. Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients.
Martin M; Trattner R; Nilsson SC; Björk A; Zickert A; Blom AM; Gunnarsson I
Front Immunol; 2020; 11():582737. PubMed ID: 33133102
[TBL] [Abstract][Full Text] [Related]
4. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.
Liu CC; Manzi S; Kao AH; Navratil JS; Ruffing MJ; Ahearn JM
Arthritis Rheum; 2005 Oct; 52(10):3087-99. PubMed ID: 16200588
[TBL] [Abstract][Full Text] [Related]
5. Glomerular c4d staining can be an indicator of disease activity in lupus nephritis.
Sahin OZ; Gurses S; Taslı F; Yavas H; Ersoy R; Uzum A; Cirit M
Ren Fail; 2013; 35(2):222-5. PubMed ID: 23176021
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study.
Batal I; Liang K; Bastacky S; Kiss LP; McHale T; Wilson NL; Paul B; Lertratanakul A; Ahearn JM; Manzi SM; Kao AH
Lupus; 2012 Jan; 21(1):13-26. PubMed ID: 21959138
[TBL] [Abstract][Full Text] [Related]
7. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis.
Cohen D; Koopmans M; Kremer Hovinga IC; Berger SP; Roos van Groningen M; Steup-Beekman GM; de Heer E; Bruijn JA; Bajema IM
Arthritis Rheum; 2008 Aug; 58(8):2460-9. PubMed ID: 18668574
[TBL] [Abstract][Full Text] [Related]
8. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.
Kao AH; Navratil JS; Ruffing MJ; Liu CC; Hawkins D; McKinnon KM; Danchenko N; Ahearn JM; Manzi S
Arthritis Rheum; 2010 Mar; 62(3):837-44. PubMed ID: 20187154
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
Li J; An L; Zhang Z
Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
[TBL] [Abstract][Full Text] [Related]
10. Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up.
Gerhardsson J; Sundelin B; Zickert A; Padyukov L; Svenungsson E; Gunnarsson I
Arthritis Res Ther; 2015 Apr; 17(1):109. PubMed ID: 25927214
[TBL] [Abstract][Full Text] [Related]
11. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus.
Yang DH; Chang DM; Lai JH; Lin FH; Chen CH
Rheumatology (Oxford); 2009 Sep; 48(9):1083-7. PubMed ID: 19553377
[TBL] [Abstract][Full Text] [Related]
13. Platelet C4d is highly specific for systemic lupus erythematosus.
Navratil JS; Manzi S; Kao AH; Krishnaswami S; Liu CC; Ruffing MJ; Shaw PS; Nilson AC; Dryden ER; Johnson JJ; Ahearn JM
Arthritis Rheum; 2006 Feb; 54(2):670-4. PubMed ID: 16447243
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus.
Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM
Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444
[TBL] [Abstract][Full Text] [Related]
15. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
[TBL] [Abstract][Full Text] [Related]
16. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
Manzi S; Navratil JS; Ruffing MJ; Liu CC; Danchenko N; Nilson SE; Krishnaswami S; King DE; Kao AH; Ahearn JM
Arthritis Rheum; 2004 Nov; 50(11):3596-604. PubMed ID: 15529364
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Erythrocyte C4d to Complement Receptor 1 Ratio: Use in Distinguishing between Infection and Flare-Up in Febrile Patients with Systemic Lupus Erythematosus.
Chen CH; Tai SB; Chen HC; Yang DH; Peng MY; Lin YF
Biomed Res Int; 2015; 2015():939783. PubMed ID: 26273660
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
19. Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus.
Haddon DJ; Diep VK; Price JV; Limb C; Utz PJ; Balboni I
Arthritis Res Ther; 2015 Jun; 17(1):162. PubMed ID: 26081107
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the phosphatase JKAP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis.
Chuang HC; Chen YM; Hung WT; Li JP; Chen DY; Lan JL; Tan TH
Oncotarget; 2016 Sep; 7(36):57593-57605. PubMed ID: 27557500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
